These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 22107757

  • 1. Anticancer activity of an imageable curcuminoid 1-[2-aminoethyl-(6-hydrazinopyridine-3-carbamidyl)-3,5-bis-(2-fluorobenzylidene)-4-piperidone (EFAH).
    Lagisetty P, Subramaniam D, Sahoo K, Anant S, Awasthi V.
    Chem Biol Drug Des; 2012 Feb; 79(2):194-201. PubMed ID: 22107757
    [Abstract] [Full Text] [Related]

  • 2. A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies.
    Bisht S, Schlesinger M, Rupp A, Schubert R, Nolting J, Wenzel J, Holdenrieder S, Brossart P, Bendas G, Feldmann G.
    J Nanobiotechnology; 2016 Jul 11; 14(1):57. PubMed ID: 27401816
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties.
    Olivera A, Moore TW, Hu F, Brown AP, Sun A, Liotta DC, Snyder JP, Yoon Y, Shim H, Marcus AI, Miller AH, Pace TW.
    Int Immunopharmacol; 2012 Feb 11; 12(2):368-77. PubMed ID: 22197802
    [Abstract] [Full Text] [Related]

  • 4. CLEFMA-an anti-proliferative curcuminoid from structure-activity relationship studies on 3,5-bis(benzylidene)-4-piperidones.
    Lagisetty P, Vilekar P, Sahoo K, Anant S, Awasthi V.
    Bioorg Med Chem; 2010 Aug 15; 18(16):6109-20. PubMed ID: 20638855
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antibacterial activity of synthetic curcumin derivatives: 3,5-bis(benzylidene)-4-piperidone (EF24) and EF24-dimer linked via diethylenetriaminepentacetic acid (EF2DTPA).
    Vilekar P, King C, Lagisetty P, Awasthi V, Awasthi S.
    Appl Biochem Biotechnol; 2014 Apr 15; 172(7):3363-73. PubMed ID: 24532443
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The curcumin analog EF24 targets NF-κB and miRNA-21, and has potent anticancer activity in vitro and in vivo.
    Yang CH, Yue J, Sims M, Pfeffer LM.
    PLoS One; 2013 Apr 15; 8(8):e71130. PubMed ID: 23940701
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis, and biological evaluation of novel EF24 and EF31 analogs as potential IκB kinase β inhibitors for the treatment of pancreatic cancer.
    Xie X, Tu J, You H, Hu B.
    Drug Des Devel Ther; 2017 Apr 15; 11():1439-1451. PubMed ID: 28553074
    [Abstract] [Full Text] [Related]

  • 11. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity.
    Subramaniam D, May R, Sureban SM, Lee KB, George R, Kuppusamy P, Ramanujam RP, Hideg K, Dieckgraefe BK, Houchen CW, Anant S.
    Cancer Res; 2008 Mar 15; 68(6):1962-9. PubMed ID: 18339878
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis, and evaluation of asymmetric EF24 analogues as potential anti-cancer agents for lung cancer.
    Wu J, Wu S, Shi L, Zhang S, Ren J, Yao S, Yun D, Huang L, Wang J, Li W, Wu X, Qiu P, Liang G.
    Eur J Med Chem; 2017 Jan 05; 125():1321-1331. PubMed ID: 27886548
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin.
    Kasinski AL, Du Y, Thomas SL, Zhao J, Sun SY, Khuri FR, Wang CY, Shoji M, Sun A, Snyder JP, Liotta D, Fu H.
    Mol Pharmacol; 2008 Sep 05; 74(3):654-61. PubMed ID: 18577686
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Multiple anticancer activities of EF24, a novel curcumin analog, on human ovarian carcinoma cells.
    Tan X, Sidell N, Mancini A, Huang RP, Shenming Wang, Horowitz IR, Liotta DC, Taylor RN, Wieser F.
    Reprod Sci; 2010 Oct 05; 17(10):931-40. PubMed ID: 20693500
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1.
    Thomas SL, Zhong D, Zhou W, Malik S, Liotta D, Snyder JP, Hamel E, Giannakakou P.
    Cell Cycle; 2008 Aug 05; 7(15):2409-17. PubMed ID: 18682687
    [Abstract] [Full Text] [Related]

  • 20. Preparation and comparative evaluation of 99m Tc-HYNIC-cNGR and 99m Tc-HYNIC-PEG2 -cNGR as tumor-targeting molecular imaging probes.
    Vats K, Satpati D, Sharma R, Kumar C, Sarma HD, Banerjee S.
    J Labelled Comp Radiopharm; 2018 Feb 05; 61(2):68-76. PubMed ID: 29139598
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.